Eva-Lotta Allan is chair at Maxion Therapeutics

Thursday 2 November 2023
Maxion Therapeutics Ltd
Appointee name
Eva-Lotta Allan

United Kingdom

Eva-Lotta Allan, an experienced biotech executive, has been appointed chair of the board of directors of Maxion Therapeutics Ltd, a UK developer of antibody drugs for autoimmune conditions and chronic pain. Ms Allan also serves as non-executive chair of the Danish biotech company Draupnir Bio ApS and as a non-executive director of Almirall SA in Spain; Aleta Biotherapeutics Inc in the US; and Crescendo Biologics Ltd in the UK. She has served as chief business officer at both Immunocore Holdings Plc and Ablynx, now part of Sanofi SA.

Ms Allan holds a degree in natural sciences from Jakobsbergskolan and in microbiology from the Laboratory School University, both in Stockholm, Sweden.

Maxion Therapeutics announced the appointment on 21 September 2023.

Copyright 2003 Evernow Publishing Ltd